Previous 10 | Next 10 |
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Marinus Pharmaceuticals Inc. (MRNS) is expected to report $-0.67 for Q3 2023
2023-11-06 11:30:48 ET More on Marinus Pharmaceuticals Evaluating Marinus: Ztalmy's Growth And Upcoming Trial Insights Marinus stock jumps 11% on financial, pipeline updates Marinus downgraded by Oppenheimer on concerns over seizure asset trial For further de...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on November 7, 2023. The Company ...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 2023 Can...
2023-09-20 17:12:25 ET Gainers: Marinus Pharmaceuticals ( NASDAQ: MRNS ) +8% . Complete Solaria ( CSLR ) +5% . Arhaus ( ARHS ) +5% . COMPASS Pathways ( CMPS ) +5% . Quantum-Si ( QSI ) +5% . Losers: Vahanna Tech ...
2023-09-19 12:36:23 ET More on Marinus Pharmaceuticals Evaluating Marinus: Ztalmy's Growth And Upcoming Trial Insights Marinus: Transforming The Seizure Market With Ganaxolone (Rating Upgrade) Marinus downgraded by Oppenheimer on concerns over seizure asset trial ...
RAISE trial enrollment trends have returned to anticipated levels; on track for topline data in the first quarter of 2024, assuming pre-defined stopping criteria for interim analysis are met Continued execution of commercial launch of ZTALMY ® (ganaxolone) with estimated net prod...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the speakers for its upcoming Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern Tim...
2023-09-04 14:38:18 ET Summary Marinus Pharmaceuticals received FDA approval for Ztalmy to treat seizures; aims to broaden its application. Marinus has strong financial standing with a cash runway until late 2024; ongoing trials on Ztalmy show potential. Recommendation: Mainta...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm PR Newswire LOS ANGELES , June 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing o...
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons or entities who purchased or otherwise acquired Marinus P...